Sentence examples for by blocking the binding from inspiring English sources
Symptoms of Alzheimer disease can be reduced in some patients by the drug memnatine, which decreases abnormal brain activity by blocking the binding of glutamate (an excitatory neurotransmitter) to certain receptors in the brain.
They exert their action by blocking the binding of AngII on the AT1 receptor.
It is thus likely that the repebody suppresses the hC5a-mediated immune response in monocytes by blocking the binding of hC5a to its receptor.
Interestingly, continuous anti-macrophage therapy with CCL2 neutralization by blocking the binding of CCL2 to CCR2-expressing monocytes impairs monocyte infiltration into primary mammary tumors and lung metastases in mice (Qian et al., 2011).
These results suggest that the conjugate can enter the nucleus, bind to its target site, presumably as a stacked dimer, and up-regulate the expression of topoIIα by blocking the binding of NF-Y.
These data support the design of therapeutics for the treatment of allergic airway disease that inhibits assembly of the high affinity IL-13 receptor signalling complex, by blocking the binding of IL-13 to IL-13Rα1 and IL-13Rα2, or the subsequent recruitment of IL-4Rα.
Vaptans work by preventing the antidiuresis caused by circulating vasopressin, by competitively blocking the binding of vasopressin to V2 receptors in the distal nephron of the kidney [ 19].
DNA methylation promotes gene silencing either by directly blocking the binding of transcription factors to DNA or by the binding of MBPs (methyl-binding proteins, e.g., MBD1, MBD2, MBD3, and MBD4), which can mediate gene repression through interaction with a co-repressor complex [ 18, 28].
Interleukin-1 receptor antagonist (IL-1ra) is an endogenous inhibitor of IL-1β, where it acts by competitively blocking the binding of IL-1β to receptors on IL-1 responsive cells [6].
Another unique property of TIMP-3 is its ability to inhibit angiogenesis by specifically blocking the binding of VEGF-A to its receptor VEGF-R2.
Enzalutamide is an antiandrogen that inhibits the transcriptional activity of AR by competitively blocking the binding of androgens to AR. Intriguingly, we found that this drug induces AR degradation by facilitating SPOP-AR interaction.
